Table 1 Outcomes of neoadjuvant FOLFIRINOX regimens in locally advanced and borderline resectable pancreatic cancer
Authors | Journal, Year | Number of Patients | Staging System | Duration (Cycles) | Radiographic Response | Surgical Resection | R0 Rate | Pathological Results |
|---|---|---|---|---|---|---|---|---|
Blazer et al. | Ann Surg Oncol 2015 | 25 LAPC 18 BRPC | AHPBA/ SSO/ SSAT | 4.9 (mean) | NA | NA | NA | NA |
Boone et al. [14] | Surg Oncol, 2013 | 13 LAPC 12 BRPC | AHPBA/ SSO/ SSAT | 5 (mean) | PD 1 Intolerable SE 1 | 5/11 | 4/5 | 1 CAP g0 4 CAP g1 |
Gunturu et al. [54] | Med Oncol, 2013 | 16 LAPC | NR | 11 (median) | PR 8 SD 7 PD 0 | 2/16 | NR | 1 near pCR (2 mm residual tumor) |
Hosein et al. [55] | BMC Cancer, 2012 | 14 LAPC 4 BRPC | AHPBA/ SSO/ SSAT | 6 (median) | LAPC (1 PD, 9 RT) BRPC (1 RT) | LAPC (3/14) BRPC (3/4) | LAPC (2/3) BRPC (3/3) | NR |
Khushman et al. [56] | Pancreatology, 2015 | 25 LAPC | AHPBA/ SSO/ SSAT | 8 (median) | PD 2 | 10/25 | 7/10 | NR |
Nitsche et al. [18] | Ann Surg Oncol, 2015 | 14 LAPC/ BRPC | NCCN | 7 (median) | 6 PR, 6 SD, 1 PD | 0/14 | NR | NR |
Peddi et al. [57] | JOP, 2012 | 19 LAPC 4 BRPC | NR | 4 (median) | 1 rCR, 5 PR, 9 SD, 3 PD | 4/23 | NR | NR |
Valeri et al. [21] | Pancreatology, 2014 | 1 LAPC | MDA | 8 | NR | 1/1 | 1/1 | 1 pCR |